… -line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced
non-small cell lung cancer in … Erlotinib versus chemotherapy (CT) in advanced non-small …

… TKIs, gefitinib and erlotinib as first-line, second-line or has the effect of maintenance therapy.
… EGFR activatingmutations in patients with non small cell lung cancer; dacomitinib are in the …

… in maintenance treatment of patients with advanced non-small … erlotinib for patients with
advanced stage non-small cell lung … Gefitinib versus placebo as maintence therapy in patients …

… 表皮生长因子受体酪氨酸激酶抑制剂（epidermal growth factor receptor tyrosine kinase inhibitor,
EGFR-TKI）是化疗失败的晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）的标准二…

… on the targeted agents for non-small cell lung cancer (NSCLC) brain metastases treatment.
The key point is the efficacy and safety. In this paper, the targeted treatments of NSCLC brain …

… treatment of non-small cell lung cancer(NSCLC). Key words: Non-small cell lung cancer(NSCLC);
Programmed cell … ); Programmed cell death-ligand 1(PD-L1); Immune targeted therapy …

… 一錠250 mg 的2.4 ~ 2.8 顆,即gefitinib 藥效強度約為erlotinib 最大 耐受劑量的三分之一,因此…
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, …

… therapy in patients with stage Ⅳ non-small cell lung … patients with stage Ⅳ EGFR
mutation-positive NSCLC receiving EGFR-TKIs (erlotinib, gefitinib, and icotinib) as the first-line …

… Erlotinib and Crizotinib, have an irreplaceable position in the therapy of advanced non-small
cell lung … 此外，有日本学者 [14] 回顾性分析了Gefitinib和Erlotinib治疗NSCLC不良反应的差异…

… reaction of agent erlotinib in advanced and previously treated non-small-cell lung cancer. …
receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, …